| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3599 | 2014 |
| Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial YL Wu, Y Cheng, X Zhou, KH Lee, K Nakagawa, S Niho, F Tsuji, R Linke, ... The Lancet Oncology 18 (11), 1454-1466, 2017 | 1120 | 2017 |
| Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial C Gridelli, F Perrone, C Gallo, S Cigolari, A Rossi, F Piantedosi, ... Journal of the National Cancer Institute 95 (5), 362-372, 2003 | 1049 | 2003 |
| Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non—small-cell lung cancer receiving … P Maione, F Perrone, C Gallo, L Manzione, FV Piantedosi, S Barbera, ... Journal of Clinical Oncology 23 (28), 6865-6872, 2005 | 567 | 2005 |
| Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations TS Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa, S Niho, M Lee, R Linke, ... Journal of Clinical Oncology, JCO. 2018.78. 7994, 2018 | 486 | 2018 |
| Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study S Novello, J Mazières, IJ Oh, J De Castro, MR Migliorino, Å Helland, ... Annals of Oncology 29 (6), 1409-1416, 2018 | 314 | 2018 |
| Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies C D’Antonio, A Passaro, B Gori, E Del Signore, MR Migliorino, S Ricciardi, ... Therapeutic advances in medical oncology 6 (3), 101-114, 2014 | 237 | 2014 |
| Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, ... Annals of Oncology 27 (3), 417-423, 2016 | 161 | 2016 |
| Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: a real‐world transverse study A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ... The oncologist 24 (6), e327-e337, 2019 | 156 | 2019 |
| Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients A Cortellini, R Chiari, B Ricciuti, G Metro, F Perrone, M Tiseo, M Bersanelli, ... Clinical lung cancer 20 (4), 237-247. e1, 2019 | 139 | 2019 |
| Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): a large retrospective … A Russo, M Russano, T Franchina, MR Migliorino, G Aprile, G Mansueto, ... Advances in therapy 37, 1145-1155, 2020 | 136 | 2020 |
| First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status F Facchinetti, G Mazzaschi, F Barbieri, F Passiglia, F Mazzoni, R Berardi, ... European Journal of Cancer 130, 155-167, 2020 | 114 | 2020 |
| Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer L Landi, F D’Incà, A Gelibter, R Chiari, F Grossi, A Delmonte, A Passaro, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 114 | 2019 |
| Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy A Mancuso, M Migliorino, S De Santis, A Saponiero, F De Marinis Annals of Oncology 17 (1), 146-150, 2006 | 107 | 2006 |
| Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab … A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ... Journal for immunotherapy of cancer 9 (4), 2021 | 100 | 2021 |
| Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death … A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ... European Journal of Cancer 128, 17-26, 2020 | 97 | 2020 |
| Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for … C Gridelli, E Kaukel, V Gregorc, MR Migliorino, TR Müller, C Manegold, ... Journal of Thoracic Oncology 2 (3), 221-229, 2007 | 95 | 2007 |
| Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR … TS Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa, S Niho, A Chawla, ... Drugs 81, 257-266, 2021 | 83 | 2021 |
| Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 77 | 2020 |
| Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50% A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ... Cancer Immunology, Immunotherapy 69, 2209-2221, 2020 | 70 | 2020 |
